Xinhuanet Harbin, May 1st issue: China has developed a new type of human live vaccine for H5N1 bird flu Xinhua News Agency reporter Fan Yingchun China National Avian Influenza Reference Laboratories recently announced the development of a new type of cold-adapted live-attenuated vaccine for human bird flu, which is expected to provide full protection against human infection with the H5N1 subtype bird flu virus. Compared with previous inactivated vaccines for human bird flu, the new live vaccines have made revolutionary progress in many aspects including immune effects, production processes, and methods of use, and are at the forefront of internationally relevant fields. The results of this research were published on the 1st issue of the international authoritative academic magazine Popular Science Library Pathogens. The scientists used a non-human primate macaque to conduct a new vaccine immunoprotection trial. The results showed that the vaccine could completely prevent the replication of the H5N1 subtype avian influenza virus in monkeys after immunization. The immune monkeys showed complete health in the experimental observation period. The challenge virus replicated extensively in the lungs of unvaccinated control monkeys, causing acute viral pneumonia, fever, loss of appetite, and other symptoms that are very similar to human infection with the avian influenza virus. Dr. Chen Hualan, director of the National Avian Influenza Reference Laboratory who presided over the study, said in an interview with the Xinhua News Agency: “We are full of confidence that the vaccine will prevent the use of human H5N1 avian influenza.†According to statistics from the World Health Organization, between 250,000 and 500,000 people die from seasonal influenza every year. The new H1N1 subtype influenza virus, which is currently erupting in Mexico and the United States, has caused new public health panic and attention to related prevention and control measures because of its strong horizontal human-to-human transmission capabilities. The World Organisation for Animal Health confirmed that the North American influenza virus has concentrated on the characteristics of swine flu virus, human influenza virus, and bird flu virus. It is a mixed influenza virus. Chen Hualan said that on the basis of research on live H5N1 vaccines, a platform established by experts from relevant international fields will be able to rapidly develop new vaccines against other emerging flu epidemics. The H5NI subtype bird flu virus is the internationally recognized and most hazardous bird flu virus and is currently prevalent in poultry or wild birds in more than 60 countries worldwide. The virus can spread from poultry to humans. Since 2003, 421 people have been infected in 15 countries, resulting in 257 deaths and a 61% mortality rate. Experts pointed out that although the H5NI human bird flu cases that have been diagnosed so far are all single features, it does not rule out the possibility that the virus will spread from person to person through respiratory channels in the future, leading to widespread catastrophic epidemics. The only effective means to prevent and control the human bird flu pandemic is to immunize people. At present, there are people in the world who have been allowed to produce H5N1 avian influenza inactivated vaccine and have a small amount of reserves. However, existing inactivated vaccines have the defects of weak immunogenicity and complicated production process, and they need to use adjuvants that may have a negative effect on human health to achieve an immune effect. The World Health Organization estimates that even if all current production capacities in all countries in the world are activated, it may take about four years before sufficient vaccines can be produced to prevent the H5N1 bird flu epidemic. The constraints of production capacity and raw materials have greatly reduced the practical feasibility of using inactivated vaccines to respond to the bird flu epidemic. Compared with the original inactivated vaccine, China National Bird Flu Reference Laboratory and experts from the University of Tokyo in Japan have successfully developed a new live vaccine that not only has a more reliable immune effect, but also has a simple method of use and can be injected from the nasal cavity. Live vaccine preparations are produced by direct lyophilization of chick embryos after reproduction, eliminating the need for long and complicated processes such as concentration, inactivation, and purification in the inactivated vaccine production process, greatly reducing production time. What is particularly optimistic is that since the content of the new live vaccine antigen is very small, only one to one thousandth of the inactivated vaccine is required for the production of chicken embryo raw materials, and thus the conditions for large-scale production and large-scale reserve are available. Chen Hualan revealed that the National Avian Influenza Reference Laboratory is actively seeking the support of relevant departments at higher levels to advance the clinical evaluation of new vaccines, with a view to putting them into production and reserves as soon as possible. Swing Glass Door Swing Systems Swing Doors have never been such a feature in the home. Utilizing heavy duty, architectural stainless steel hinges and our robust door panels engineered for taller and wider openings, our new swing doors create more space than typical single and French doors. Our signature narrow stile and rail swing doors perfectly match our Folding and Multi Slide systems to create all-around balance and symmetry; the ideal solution for a complete door package. Glass Saloon Doors,Double Swing Glass Door,Swing Door Glass,Aluminum Glass Swing Door Leader Hardware Manufacturer Limited , https://www.leaderhardwarecn.com